Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Significant Increase in Short Interest

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 186,100 shares, an increase of 6.3% from the September 30th total of 175,000 shares. Based on an average daily trading volume, of 50,700 shares, the days-to-cover ratio is presently 3.7 days. Approximately 1.3% of the company's shares are short sold.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on COYA shares. HC Wainwright started coverage on Coya Therapeutics in a research report on Monday, September 16th. They set a "buy" rating and a $18.00 target price for the company. Chardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company's stock worth $8,407,000 after purchasing an additional 750,338 shares in the last quarter. GHP Investment Advisors Inc. bought a new position in Coya Therapeutics during the third quarter worth about $169,000. Renaissance Technologies LLC acquired a new position in Coya Therapeutics in the second quarter valued at about $101,000. Finally, Gilbert & Cook Inc. bought a new stake in shares of Coya Therapeutics in the second quarter worth about $61,000. Institutional investors and hedge funds own 39.75% of the company's stock.

Coya Therapeutics Trading Down 2.6 %

Shares of NASDAQ:COYA traded down $0.19 during midday trading on Friday, hitting $7.04. The company had a trading volume of 80,105 shares, compared to its average volume of 71,927. Coya Therapeutics has a 12 month low of $4.40 and a 12 month high of $10.69. The firm has a fifty day simple moving average of $6.91 and a 200 day simple moving average of $7.09. The stock has a market cap of $107.15 million, a price-to-earnings ratio of -9.64 and a beta of 0.58.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. The business had revenue of $3.43 million during the quarter. Equities analysts forecast that Coya Therapeutics will post -1.27 EPS for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.